Free Trial

CERo Therapeutics (CERO) Competitors

CERo Therapeutics logo
$9.36 -0.10 (-1.06%)
Closing price 07/3/2025 03:44 PM Eastern
Extended Trading
$9.28 -0.07 (-0.80%)
As of 07/3/2025 04:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CERO vs. NKGN, EDSA, SYBX, RLYB, IMNN, FLGC, ALVR, ERNA, ME, and NEUP

Should you be buying CERo Therapeutics stock or one of its competitors? The main competitors of CERo Therapeutics include NKGen Biotech (NKGN), Edesa Biotech (EDSA), Synlogic (SYBX), Rallybio (RLYB), Imunon (IMNN), Flora Growth (FLGC), AlloVir (ALVR), Ernexa Therapeutics (ERNA), 23andMe (ME), and Neuphoria Therapeutics (NEUP). These companies are all part of the "pharmaceutical products" industry.

CERo Therapeutics vs. Its Competitors

NKGen Biotech (NYSE:NKGN) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are held by institutional investors. 10.4% of NKGen Biotech shares are held by insiders. Comparatively, 12.7% of CERo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

CERo Therapeutics has a consensus target price of $45.00, suggesting a potential upside of 380.77%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CERo Therapeutics is more favorable than NKGen Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NKGen Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
CERo Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NKGen BiotechN/AN/A-$82.94M-$2.45-0.12
CERo TherapeuticsN/AN/A-$8.30MN/AN/A

NKGen Biotech has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, CERo Therapeutics has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500.

Company Net Margins Return on Equity Return on Assets
NKGen BiotechN/A N/A -479.36%
CERo Therapeutics N/A N/A -199.71%

In the previous week, NKGen Biotech's average media sentiment score of 0.00 equaled CERo Therapeutics'average media sentiment score.

Company Overall Sentiment
NKGen Biotech Neutral
CERo Therapeutics Neutral

Summary

CERo Therapeutics beats NKGen Biotech on 7 of the 9 factors compared between the two stocks.

Get CERo Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CERO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CERO vs. The Competition

MetricCERo TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.58M$2.43B$5.55B$9.04B
Dividend YieldN/A1.67%5.22%3.99%
P/E RatioN/A9.3527.6620.24
Price / SalesN/A691.51419.21118.06
Price / CashN/A158.5936.8958.10
Price / Book-0.224.588.035.67
Net Income-$8.30M$31.34M$3.18B$249.21M
7 Day Performance-1.99%3.25%2.93%3.28%
1 Month Performance2.97%3.46%1.72%3.95%
1 Year Performance-98.16%0.77%34.39%20.98%

CERo Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CERO
CERo Therapeutics
3.2725 of 5 stars
$9.36
-1.1%
$45.00
+380.8%
-98.2%$3.58MN/A0.008
NKGN
NKGen Biotech
N/A$0.32
-3.5%
N/A-77.6%$14.32MN/A-0.06N/A
EDSA
Edesa Biotech
1.0521 of 5 stars
$2.03
flat
$5.00
+146.3%
-51.5%$14.25MN/A-1.2820
SYBX
Synlogic
0.5112 of 5 stars
$1.18
-7.1%
N/A-18.6%$13.81M$10K-0.4780Gap Up
RLYB
Rallybio
2.1759 of 5 stars
$0.33
-2.3%
$10.00
+2,927.6%
-74.6%$13.74M$640K-0.3040
IMNN
Imunon
2.1008 of 5 stars
$0.78
-2.4%
$15.50
+1,884.1%
-41.8%$13.70M$500K-0.5730News Coverage
Analyst Upgrade
FLGC
Flora Growth
3.0115 of 5 stars
$0.60
+3.4%
$4.00
+566.7%
-31.0%$13.54M$59.51M-0.61280News Coverage
ALVR
AlloVir
N/A$2.67
+1.9%
N/A-84.5%$13.47MN/A-0.13110Gap Up
ERNA
Ernexa Therapeutics
N/A$1.82
-1.1%
N/A-93.1%$13.40M$580K-0.2210
ME
23andMe
N/A$0.50
-35.3%
N/A-94.2%$13.36M$208.78M-0.03770Gap Down
High Trading Volume
NEUP
Neuphoria Therapeutics
1.3276 of 5 stars
$7.02
-1.1%
$21.00
+199.1%
N/A$13.20M$10K0.00N/A

Related Companies and Tools


This page (NASDAQ:CERO) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners